Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Aktis Oncology, Inc.NASDAQ: AKTS
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets of $3.26M in Q1 FY2026
Q1 FY2026 other current assets was $3.26M. Over 3 fiscal years it compounded at -3.2% a year.
Context
- Other current assets amounted to 0.6% of total assets at the end of Q1 FY2026.
- Other current assets increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 3.52M USD
- Year-over-year change
- -4.4%
- 3-year CAGR
- -3.2%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.52M | -4.4% |
| FY2024 | 2024-12-31 | 3.69M | +57.3% |
| FY2023 | 2023-12-31 | 2.34M | -39.7% |
| FY2022 | 2022-12-31 | 3.88M | — |
Other Current Assets vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 other current assets of $3.26M is the 5th highest of the 6 companies compared; the peer median is $16.21M.
- Other current assets amounts to 0.6% of total assets for AKTS, versus a peer median of 3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $69.59M | +66.9% | +142.9% | 6.5% | |
| Mar 2026 | $18.74M | +12.0% | — | 2.9% | |
| Sep 2026 | $16.21M | +122.6% | — | 3.2% | |
| Mar 2026 | $8.37M | +4.9% | -4.9% | 3.8% | |
| Mar 2026 | $3.26M | — | -3.2% | 0.6% | |
| Mar 2026 | $1.06M | -40.1% | -41.0% | 0.8% | |
| Peer median (excluding AKTS) | $16.21M | +12.0% | -4.9% | 3.2% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.